about
The use and abuse of commercial kits used to detect autoantibodiesSystemic sclerosis: commonly asked questions by rheumatologistsAutoantibodies in systemic sclerosis: unanswered questionsClinical and serological evaluation of a novel CENP-A peptide based ELISARole of 2D strain in the early identification of left ventricular dysfunction and in the risk stratification of systemic sclerosis patients.Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF).Mercury exposure, serum antinuclear/antinucleolar antibodies, and serum cytokine levels in mining populations in Amazonian Brazil: a cross-sectional study.Comparing HLA shared epitopes in French Caucasian patients with scleroderma.The U1-snRNP complex: structural properties relating to autoimmune pathogenesis in rheumatic diseases.Myositis autoantibodies and clinical phenotypes.Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.Antinuclear antibody-negative systemic sclerosis.Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequencyExacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentanAnti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus.The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis.Pulmonary involvement in systemic sclerosis: A clinical profile.Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses.Exercise capacity in relation to autoantibodies in systemic sclerosis patients.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures PerspectivesClinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.Biomarkers in systemic sclerosis.Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.A system out of breath: how hypoxia possibly contributes to the pathogenesis of systemic sclerosis.Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement.A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.Low doses of mercuric chloride cause the main features of anti-nucleolar autoimmunity in female outbred CFW mice.The changing landscape of the clinical value of the PM/Scl autoantibody system.Increased expression of S100A8 and S100A9 in patients with diffuse cutaneous systemic sclerosis. A correlation with organ involvement and immunological abnormalities.Interstitial lung disease in South Africans with systemic sclerosis.A systematic review of the epidemiology, disease characteristics and management of systemic sclerosis in Australian adults.Unmet Needs in Systemic Sclerosis Understanding and Treatment: the Knowledge Gaps from a Scientist's, Clinician's, and Patient's Perspective.A protein fragment derived from DNA-topoisomerase I as a novel tumour-associated antigen for the detection of early stage carcinoma.Serum Soluble Vascular Cell Adhesion Molecule-1 Overexpression Is a Disease Marker in Patients with First-Time Diagnosed Antinuclear Antibodies: A Prospective, Observational Pilot Study.Early identification of vascular damage in patients with systemic sclerosis.Evaluation and management approaches for scleroderma lung disease.Cerebellar atrophy in systemic sclerosis.
P2860
Q24805079-705ADC28-8CB5-44AC-92FE-1D5A4C00A4FDQ27021067-12467191-4DE5-45E0-BBD1-AD6F28140D7FQ28085026-EA72FFF9-03F7-437F-BCFE-3358E2CCEF08Q28750130-EBC4C179-6D5C-44E9-894A-BC80FFACA5E0Q30458135-0BE6A5EF-10BD-4385-AD41-ABA28204666FQ33737250-3EF07BBE-412F-4A77-8C25-0547D9C523E1Q33863272-F69D6408-3481-4E95-BDE0-3BB04C55D03BQ34277474-F162DC8D-F1EF-46F4-90A6-EB292E390D5DQ34779998-EF36742A-9237-422A-9758-BFD2A46C75F4Q35281962-57B8CFE0-68E1-4FF0-B752-74550E64AB1DQ35352582-38CBE992-38AD-44DB-A8E0-2746EF27186FQ35661256-2175CC45-3068-401D-A962-24D5372893A2Q35954658-4CC96D74-9AC0-4716-87D1-D10F14B6614CQ35975992-5672A22C-8483-4AD2-9428-F9A0DC7F3981Q36129874-CB6EC65E-6158-4825-BBC6-9E7F8C011752Q36592069-231D95A0-653F-4CF9-A33F-BFC18E487608Q36701466-56963689-6EC1-43B8-AFDD-F7D8AB0A127BQ36917458-D0752033-9FF2-4A0C-9D34-5476306948A9Q37300987-CBD449E3-6C88-4FCE-9BB9-5B4DF31959C2Q37381549-03427B50-78EE-4C7F-BE83-27F0C6455762Q37690559-BC967AD7-FD17-48F3-81E1-8DC98FF43FBEQ37730018-1BC70FDD-062C-4C11-A60C-6453796D0752Q38156227-EC7287D2-FE22-4DDD-A0AD-31902B236AB5Q39519878-4D21D2AE-3E3B-46B5-910F-FB459830E5F2Q40153822-1216C76F-BE3E-41FA-8C79-FA9BB4F818C7Q40491920-6ABABBDD-4892-43F2-9CAA-CFF48BEBB1B1Q40891723-9C11C191-C3E2-4DD8-8474-16DA332BA94BQ41235272-E64CEA2C-1552-4316-A0E1-F3CD046C00FCQ43120878-59CC3C11-C1A8-4943-9ECC-2CA5561CFBA2Q44751936-5F3E88D6-2715-4DFF-AD4B-DAC01DF437CFQ46176565-FD384226-BFDE-40D5-9C7C-4671ADC6F996Q48115705-F2C1E5AD-056F-483C-AABC-814EF6FC6053Q50230077-A51BBA79-48BF-48A6-8D43-83793A9A1FDFQ50304651-E9EC2FDE-DCC4-4BA5-BC57-4AB7B411F849Q50329525-F0488D45-5C8B-4CAB-A84D-2562B40367FAQ50683587-9F278ECD-E5C4-4D55-9F57-977711518B2BQ52939870-45CB3AB3-F90D-4800-B078-40C260FFE93FQ55396705-40D5C337-3B51-40DF-A1FC-25479069B334
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The clinical relevance of autoantibodies in scleroderma
@ast
The clinical relevance of autoantibodies in scleroderma
@en
The clinical relevance of autoantibodies in scleroderma
@nl
type
label
The clinical relevance of autoantibodies in scleroderma
@ast
The clinical relevance of autoantibodies in scleroderma
@en
The clinical relevance of autoantibodies in scleroderma
@nl
prefLabel
The clinical relevance of autoantibodies in scleroderma
@ast
The clinical relevance of autoantibodies in scleroderma
@en
The clinical relevance of autoantibodies in scleroderma
@nl
P2860
P921
P3181
P356
P1476
The clinical relevance of autoantibodies in scleroderma
@en
P2093
John D Reveille
Khanh T Ho
P2860
P2888
P3181
P356
10.1186/AR628
P407
P577
2003-02-12T00:00:00Z
P5875
P6179
1037644695